SynthesisFrontiers in medicine2026
Acute kidney injury incidence and mortality following spontaneous intracerebral hemorrhage: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intracerebral hemorrhage (ICH) is a neurological emergency that is frequently associated with high mortality and severe disability. Acute kidney injury (AKI) is a common in-hospital complication of ICH, and it is linked to increased mortality risk and poor functional outcomes. However, there have been inconsistent AKI diagnostic criteria across relevant studies in recent years, and there is a lack of updated comprehensive evidence regarding the association between ICH treatment and AKI risk. Therefore, this study aims to systematically investigate the incidence rate of AKI following ICH and its association with mortality in ICH patients. Methods: We conducted a comprehensive literature search in the Embase, PubMed, and Scopus databases up to April 1, 2025. Two independent reviewers performed data extraction and assessed risk of bias. The Newcastle-Ottawa Scale (NOS) was used for cohort studies, while the Risk of Bias 2 (RoB 2) tool was applied for randomized clinical trials, respectively. Results: A total of 12 studies, with a total of 16,199 patients, were included in this meta-analysis. The pooled incidence rate of AKI following ICH was 20.4% (95% confidence interval [CI]: 15.2-25.6%). Subgroup analysis based on AKI diagnostic criteria revealed that the incidence rate of AKI diagnosed by KDIGO was higher than that diagnosed by the AKIN. Further analysis of AKI stages showed that stage 1 AKI was the most common type among ICH patients, accounting for a pooled proportion of 75.6% (95% CI: 59.9-91.4%), while stages 2 and 3 AKI had similar proportions. Additionally, AKI was linked to a higher short-term mortality risk in ICH patients, with a pooled odds ratio (OR) of 3.16 (95% CI: 1.93-5.18). Conclusion: AKI is common in ICH and associated with higher short-term mortality. Future studies should focus on early AKI biomarkers, individualized blood pressure control and long-term prognosis. Systematic review registration: CRD42025642481.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.